Evidence mapPaperPMID 42589528Full record

ReviewInternational journal of molecular sciences2026

Terpenoids as Emerging Senotherapeutics: Mechanistic Insights and Therapeutic Potential.

Sungwoo Yi, Jung Yoon Park, Sung-Joon Lee

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sungwoo YiDepartment of Biotechnology, Graduate School of Biotechnology, Korea University, Seoul 02841, Republic of Korea.
Jung Yoon ParkDepartment of Biotechnology, Graduate School of Biotechnology, Korea University, Seoul 02841, Republic of Korea.
Sung-Joon LeeDepartment of Biotechnology, Graduate School of Biotechnology, Korea University, Seoul 02841, Republic of Korea.ORCID 0000-0001-8683-3377

Funding

National Research Foundation of Korea RS2023-00223831National Research Foundation of Korea RS2024-00349390
6 · The paper itself

Abstract

Cellular senescence, characterized by stable cell cycle arrest, drives organismal aging and functional decline. Senescent cells (SnCs) increase in multiple tissues with age and contribute to pathology by resisting apoptosis, impairing regeneration, and releasing senescence-associated secretory phenotype (SASP) factors. Senotherapeutics, including senolytics and senomorphics, aim to reduce the impact of SnCs by selectively clearing SnCs or suppressing SASP production. Natural terpenoids are structurally diverse plant- and fungus-derived metabolites with antioxidant, anti-inflammatory, and cytoprotective properties. Growing evidence supports their ability to counteract senescence-associated phenotypes, including senescence-associated β-galactosidase (SA-β-gal) activity and the expression of p53, p21, and p16. In this review, we examine mono-, sesqui-, di-, and triterpenoids that modulate cell cycle regulation, SASP attenuation, redox homeostasis, mitochondrial function, autophagy, and apoptosis-related mechanisms. We also outline the principal pathways underlying these anti-senescence activities and highlight natural terpenoids as emerging modulators of cellular senescence.

Indexed as

Cellular SenescenceSenotherapeuticsTerpenesAnimalsApoptosisAutophagyHumansSenescence-Associated Secretory PhenotypeSenotherapeuticsTerpenesagingcellular senescencenatural compoundssenotherapeuticsterpenoid

Identifiers

PMID42589528
PMCPMC13467052

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.